Ranibizumab
- Generic Name
- Ranibizumab
- Brand Names
- Byooviz, Cimerli, Lucentis, Susvimo, Ranivisio, Rimmyrah, Ximluci
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 347396-82-1
- Unique Ingredient Identifier
- ZL1R02VT79
- Background
Ranibizumab is a recombinant humanized IgG1 kappa isotype monoclonal antibody fragment directed against human vascular endothelial growth factor A (VEGF-A), which is a glycoprotein implicated in the pathophysiology of age-related macular degeneration. Ranibizumab is used to treat various ocular disorders with abnormal growth of blood vessels, such as neovasc...
- Indication
Ranibizumab injection for intravitreal use is indicated to treat Neovascular (wet) Age-related Macular Degeneration (AMD), macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
...
- Associated Conditions
- Diabetic Macular Edema (DME), Diabetic Retinopathy (DR), Macular Edema, Myopic Choroidal Neovascularization, Neovascular Age-Related Macular Degeneration (nAMD)
- Associated Therapies
- -
A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
- First Posted Date
- 2024-08-26
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- EyeBiotech Ltd.
- Target Recruit Count
- 960
- Registration Number
- NCT06571045
- Locations
- 🇺🇸
Danbury, CT, Danbury, Connecticut, United States
🇺🇸Gainesville, FL, Gainesville, Florida, United States
🇺🇸Tallahassee, FL, Tallahassee, Florida, United States
A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- Conditions
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Outlook Therapeutics, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT06190093
- Locations
- 🇺🇸
Clinical Site, Silverdale, Washington, United States
A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopia
- Conditions
- Interventions
- First Posted Date
- 2023-12-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 280
- Registration Number
- NCT06176352
- Locations
- 🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of
🇦🇺South West Retina, Liverpool, New South Wales, Australia
🇦🇺Strathfield Retina Clinic, Strathfield, New South Wales, Australia
This Study Will Compare the Efficacy and Safety of SCT510A Administered by Intravitreal Injection (IVT) With Ranibizumab in Patients With wAMD
- Conditions
- Interventions
- First Posted Date
- 2022-07-29
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Sinocelltech Ltd.
- Target Recruit Count
- 446
- Registration Number
- NCT05480293
- Locations
- 🇨🇳
Beijing Tongren Hospital, Beijing, China
Ranibizumab Versus Aflibercept for CRVO in Young Patients.
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2022-03-16
- Lead Sponsor
- South Valley University
- Target Recruit Count
- 40
- Registration Number
- NCT05282420
- Locations
- 🇪🇬
Ahmed Ali Ahmed Amer, Qinā, Qena, Egypt
Anti-VEGF in Real-world
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2022-02-03
- Lead Sponsor
- Wenbin Wei
- Target Recruit Count
- 1000
- Registration Number
- NCT05222633
- Locations
- 🇨🇳
Wen-Bin Wei, Beijing, Beijing, China
A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 394
- Registration Number
- NCT05151731
- Locations
- 🇺🇸
Win Retina, Arcadia, California, United States
🇺🇸Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸Retina Consultants, San Diego, Poway, California, United States
A Study to Investigate Vamikibart (RO7200220) in Combination With Ranibizumab in Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 187
- Registration Number
- NCT05151744
- Locations
- 🇺🇸
Win Retina, Arcadia, California, United States
🇺🇸Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center, Torrance, California, United States
🇺🇸Bay Area Retina Associates, Walnut Creek, California, United States
A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration
- Conditions
- Interventions
- First Posted Date
- 2021-11-19
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT05126966
- Locations
- 🇭🇰
Hong Kong Eye Hospital; CUHK Eye Centre, Mongkok, Hong Kong
🇵🇹Hospital de Sao Joao; Servico de Oftalmologia, Porto, Portugal
🇩🇰Sjællands Universitetshospital, Roskilde; Øjenafdelingen, Roskilde, Denmark
601 Versus Ranibizumab in Patients With Pathological Myopic Choroidal Neovascularization (pmCNV)
- Conditions
- Interventions
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2021-06-10
- Target Recruit Count
- 60
- Registration Number
- NCT04922151
- Locations
- 🇨🇳
Peking Union Medical College Hospital, BeiJing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.